ATG3

Across TCGA pan-cancer cohorts, ATG3 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ATG3’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ATG3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ATG3 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, THCA, and HNSC are the cancer types where ATG3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATG3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.991	<.001	9	view →
THCA	Male	III,IV	−0.445	<.001	9	view →
HNSC	Male	IV	+0.908	<.001	8	view →
STAD	All	II,III,IV	+0.522	<.001	8	view →
COAD	All	II,III,IV	+0.382	<.001	8	view →
BLCA	All	All	+0.355	.004	7	view →
BRCA	All	III,IV	+0.363	<.001	6	view →
CHOL	All	All	+1.315	<.001	5	view →
LUSC	All	All	+0.385	<.001	4	view →
KICH	All	All	−0.525	.003	3	view →
UCEC	All	III,IV	+0.574	.019	2	view →
ESCA	All	All	+0.504	.008	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ATG3–LIHC

Open the LIHC breakdown →